دورية أكاديمية
Efficacy of a multiple-indication antiviral herbal drug (Saliravira®) for COVID-19 outpatients: A pre-clinical and randomized clinical trial study.
| العنوان: | Efficacy of a multiple-indication antiviral herbal drug (Saliravira®) for COVID-19 outpatients: A pre-clinical and randomized clinical trial study. |
|---|---|
| المؤلفون: | Khorshiddoust RR; R&D Group, MIM Pharma, Oslo, Norway. Electronic address: dr.ramazani@mimpharma.com., Khorshiddoust SR; R&D Group, MIM Pharma, Oslo, Norway., Hosseinabadi T; Department of Pharmacognosy and Pharmaceutical Biotechnology, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Electronic address: t.hosseinabadi@sbmu.ac.ir., Mottaghitalab F; R&D Group, MIM Pharma, Oslo, Norway. Electronic address: Faezeh.mottaghitalab@gmail.com., Mokhtari F; R&D Group, MIM Pharma, Oslo, Norway., Azadinia F; R&D Group, MIM Pharma, Oslo, Norway., Mozdarani H; Department of Medical Genetics, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran., Shabani M; Department of Biochemistry, School of Medicine, Iran University of Medical Sciences, Tehran, Iran., Emadi-Kouchak H; Department of Infectious Diseases, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran., Taheri B; Nexus & HSE Center, Amirkabir University of Technology, Tehran, Iran., Khani-Juyabad F; R&D Group, MIM Pharma, Oslo, Norway., Kashani MA; R&D Group, MIM Pharma, Oslo, Norway., Sadoughi A; Aramesh Multi-Professional Pain Clinic, Tehran, Iran., Zamanizadeh S; Aramesh Multi-Professional Pain Clinic, Tehran, Iran., Maddah H; Aramesh Multi-Professional Pain Clinic, Tehran, Iran., Aminzadeh M; Aramesh Multi-Professional Pain Clinic, Tehran, Iran., Khanaki M; Aramesh Multi-Professional Pain Clinic, Tehran, Iran., Saremi S; Aramesh Multi-Professional Pain Clinic, Tehran, Iran., Rad AP; Aramesh Multi-Professional Pain Clinic, Tehran, Iran., Fatehi A; Department of Industrial Engineering and Management Systems, Amirkabir University of Technology, Tehran, Iran., Rad MG; R&D Group, MIM Pharma, Oslo, Norway., Haftbaradaran M; MIM Daroo, Tehran, Iran., Khosroshahi M; MIM Daroo, Tehran, Iran., Sadeghi M; MIM Daroo, Tehran, Iran., Aminnayeri M; Aramesh Multi-Professional Pain Clinic, Tehran, Iran., Jafari S; Department of Infectious Diseases, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran., Ghiasvand F; Department of Infectious Diseases, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran., Seifi A; Department of Infectious Diseases, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran., Ghaderkhani S; Department of Infectious Diseases, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran., Manshadi SAD; Department of Infectious Diseases, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran., Salehi M; Department of Infectious Diseases, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran., Abbasian L; Department of Infectious Diseases, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran., Hasannezhad M; Department of Infectious Diseases, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran., Meidani M; Department of Infectious Diseases, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran., Hajiabdolbaghi M; Department of Infectious Diseases, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran., Ahmadinejad Z; Department of Infectious Diseases, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran., Parash M; Department of Infectious Diseases, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran., Sedighi Z; Department of Infectious Diseases, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran., Mohammadian A; Department of Infectious Diseases, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran. |
| المصدر: | Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie [Biomed Pharmacother] 2022 May; Vol. 149, pp. 112729. Date of Electronic Publication: 2022 Feb 17. |
| نوع المنشور: | Journal Article; Randomized Controlled Trial |
| اللغة: | English |
| بيانات الدورية: | Publisher: Editions Scientifiques Elsevier Country of Publication: France NLM ID: 8213295 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1950-6007 (Electronic) Linking ISSN: 07533322 NLM ISO Abbreviation: Biomed Pharmacother Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Paris : Editions Scientifiques Elsevier Original Publication: New York, N.Y. : Masson Pub. USA, Inc., c1982- |
| مواضيع طبية MeSH: | COVID-19 Drug Treatment*, Antiviral Agents/therapeutic use ; Humans ; Outpatients ; Pandemics ; SARS-CoV-2 ; Treatment Outcome |
| مستخلص: | Background: The scientific researches on COVID-19 pandemic topics are headed to an explosion of scientific literature. Despite these global efforts, the efficient treatment of patients is an in-progress challenge. Based on a meta-study of published shreds of evidence about compounds and their botanic sources in the last six decades, a novel multiple-indication herbal compound (Saliravira®) has been developed. Based on the antiviral, anti-inflammatory, and immune-enhancing properties of its ingredients, we hypothesized that Saliravira® has the potential to act as an antiviral agent, accelerate treatment, and reduce undesirable effects of COVID-19. Methods: In this randomized, controlled, open-label clinical trial, COVID-19 outpatients were included by RT-PCR test or diagnosis of physicians according to the symptoms. Participants were randomly divided into intervention and control groups to receive Saliravira® package plus routine treatments of COVID-19 or routine treatments of COVID-19 alone, respectively. Saliravira® package includes tablets, nasal-sinuses spray, oral-pharynx spray, and inhaler drops. The treatment was for 10 days and followed up till 23 days after admission. Results: On the 8th day, the "mean reduction rates" of viral load of the patients in the intervention group was 50% lower compared to the control group with a p-value < 0.05. The improvement of 10 out of 14 COVID-19 symptoms in the intervention group was significantly accelerated. The mean treatment duration of patients in the intervention group was 4.9 days less than the control group. In addition, no patients in the intervention group were hospitalized compared to 28% of the control group needed to be hospitalized. (Copyright © 2022. Published by Elsevier Masson SAS.) |
| References: | JAMA. 2020 Aug 25;324(8):782-793. (PMID: 32648899) Clin Exp Med. 2021 May;21(2):167-179. (PMID: 33128197) Transfusion. 2006 Oct;46(10):1770-7. (PMID: 17002634) BMC Res Notes. 2019 Jun 4;12(1):315. (PMID: 31164174) BMC Med Res Methodol. 2004 Nov 09;4:26. (PMID: 15535880) Scientometrics. 2021;126(6):5305-5319. (PMID: 33994601) Lancet Glob Health. 2020 Oct;8(10):e1249-e1250. (PMID: 32828171) Nat Rev Microbiol. 2021 Mar;19(3):141-154. (PMID: 33024307) Scientifica (Cairo). 2020 Dec 23;2020:6307457. (PMID: 33425427) Lancet. 2022 Jan 29;399(10323):417-419. (PMID: 35065006) Biomed Pharmacother. 2021 Oct;142:112015. (PMID: 34388532) Trends Microbiol. 2021 Mar;29(3):224-237. (PMID: 33451855) Biomed Pharmacother. 2022 Mar;147:112658. (PMID: 35066300) J Biosaf Biosecur. 2021 Jun;3(1):1-3. (PMID: 33521591) Nat Med. 2022 Jan;28(1):20-23. (PMID: 35039657) Eur J Microbiol Immunol (Bp). 2022 Jan 21;11(4):87-94. (PMID: 35060921) Front Public Health. 2020 Jul 29;8:383. (PMID: 32850602) Biomed Pharmacother. 2021 Jun;138:111518. (PMID: 33774315) Mol Pharm. 2021 Mar 1;18(3):754-771. (PMID: 33464914) Environ Chem Lett. 2022;20(4):2215-2225. (PMID: 35069059) J Biomol Struct Dyn. 2022 Jan 19;:1-13. (PMID: 35043750) Biomed Pharmacother. 2021 May;137:111352. (PMID: 33550050) Essays Biochem. 2018 Oct 26;62(4):487-500. (PMID: 30287586) Viruses. 2020 Mar 27;12(4):. (PMID: 32230900) Nature. 2020 Jul;583(7816):459-468. (PMID: 32353859) J Infect Public Health. 2020 Sep;13(9):1210-1223. (PMID: 32561274) Indian J Microbiol. 2021 Mar;61(1):10-15. (PMID: 33390627) Int J Med Sci. 2020 Jul 9;17(12):1803-1810. (PMID: 32714083) Infect Dis Ther. 2020 Dec;9(4):715-720. (PMID: 33051827) |
| فهرسة مساهمة: | Keywords: Antiviral agent; COVID-19; Herbal medicine; Immune-enhancing; Outpatient; Saliravira |
| المشرفين على المادة: | 0 (Antiviral Agents) |
| تواريخ الأحداث: | Date Created: 20220311 Date Completed: 20220427 Latest Revision: 20221221 |
| رمز التحديث: | 20240628 |
| مُعرف محوري في PubMed: | PMC8850097 |
| DOI: | 10.1016/j.biopha.2022.112729 |
| PMID: | 35276467 |
| قاعدة البيانات: | MEDLINE |
Full Text via ClinicalKey 
Full Text Finder | تدمد: | 1950-6007 |
|---|---|
| DOI: | 10.1016/j.biopha.2022.112729 |